PMID- 36891058
OWN - NLM
STAT- MEDLINE
DCOM- 20230310
LR  - 20230314
IS  - 1664-2392 (Print)
IS  - 1664-2392 (Electronic)
IS  - 1664-2392 (Linking)
VI  - 14
DP  - 2023
TI  - The relationship between the monocyte-to-lymphocyte ratio and osteoporosis in 
      postmenopausal females with T2DM: A retrospective study in Chinese population.
PG  - 1112534
LID - 10.3389/fendo.2023.1112534 [doi]
LID - 1112534
AB  - INTRODUCTION: The risk of fragility fractures is increased in patients with type 
      2 diabetes mellitus (T2DM). Many reports indicate that inflammatory and immune 
      responses are associated with osteoporosis and osteopenia. The 
      monocyte-to-lymphocyte ratio (MLR) is a novel potential marker of inflammatory 
      and immune responses. The present study evaluated the associations between the 
      MLR and osteoporosis in postmenopausal females with T2DM. METHODS: Data were 
      obtained from 281 T2MD postmenopausal females, and divided into three groups: 
      Osteoporosis group, osteopenia group and normal BMD group. RESULT: Data analyses 
      revealed that the MLR was significantly lower in T2MD postmenopausal females with 
      osteoporosis than in those with osteopenia and normal BMD. Logistic regression 
      showed that the MLR was an independent protective factor for osteoporosis in 
      postmenopausal females with T2DM (odds ratio [OR]: 0.015, 95% confidence interval 
      [CI]: 0.000-0.772). Based on the receiver operating characteristic (ROC) curve, 
      the MLR for diagnosing osteoporosis in postmenopausal females with T2DM was 
      projected to be 0.1019, an area under the curve of 0.761 (95% CI: 0.685-0.838), a 
      sensitivity of 74.8% and a specificity of 25.9%. CONCLUSIONS: The MLR have a high 
      efficacy in diagnosis for osteoporosis in postmenopausal females with T2DM. MLR 
      have the potential to be used as diagnosis marker for osteoporosis in 
      postmenopausal females with T2DM.
CI  - Copyright (c) 2023 Li, Zhang, Zhang, Zhang, Zhu, Xie and Wang.
FAU - Li, Hailin
AU  - Li H
AD  - Department of General Family Medicine, Renmin Hospital of Wuhan University, 
      Wuhan, China.
FAU - Zhang, Xinqi
AU  - Zhang X
AD  - Department of General Family Medicine, Renmin Hospital of Wuhan University, 
      Wuhan, China.
FAU - Zhang, Qi
AU  - Zhang Q
AD  - Department of General Family Medicine, Renmin Hospital of Wuhan University, 
      Wuhan, China.
FAU - Zhang, Qiong
AU  - Zhang Q
AD  - Department of General Family Medicine, Renmin Hospital of Wuhan University, 
      Wuhan, China.
FAU - Zhu, Xueying
AU  - Zhu X
AD  - Department of General Family Medicine, Renmin Hospital of Wuhan University, 
      Wuhan, China.
FAU - Xie, Tuxiu
AU  - Xie T
AD  - Department of General Family Medicine, Renmin Hospital of Wuhan University, 
      Wuhan, China.
FAU - Wang, Shuo
AU  - Wang S
AD  - Department of Endocrinology & Metabolism, Renmin Hospital of Wuhan University, 
      Wuhan, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20230220
PL  - Switzerland
TA  - Front Endocrinol (Lausanne)
JT  - Frontiers in endocrinology
JID - 101555782
SB  - IM
MH  - Humans
MH  - Female
MH  - Retrospective Studies
MH  - *Diabetes Mellitus, Type 2/complications/epidemiology
MH  - Monocytes
MH  - Postmenopause
MH  - East Asian People
MH  - *Osteoporosis/diagnosis/epidemiology/complications
MH  - Lymphocytes
MH  - *Bone Diseases, Metabolic
PMC - PMC9987332
OTO - NOTNLM
OT  - T2DM
OT  - monocyte-to-lymphocyte
OT  - osteoporosis
OT  - postmenopausal females
OT  - retrospective study
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2023/03/10 06:00
MHDA- 2023/03/11 06:00
PMCR- 2023/01/01
CRDT- 2023/03/09 02:08
PHST- 2022/11/30 00:00 [received]
PHST- 2023/01/30 00:00 [accepted]
PHST- 2023/03/09 02:08 [entrez]
PHST- 2023/03/10 06:00 [pubmed]
PHST- 2023/03/11 06:00 [medline]
PHST- 2023/01/01 00:00 [pmc-release]
AID - 10.3389/fendo.2023.1112534 [doi]
PST - epublish
SO  - Front Endocrinol (Lausanne). 2023 Feb 20;14:1112534. doi: 
      10.3389/fendo.2023.1112534. eCollection 2023.